Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.52
ABBV's Cash to Debt is ranked higher than
61% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ABBV: 0.52 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 0.52

Equity to Asset 0.16
ABBV's Equity to Asset is ranked lower than
54% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ABBV: 0.16 )
ABBV' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.16

-0.01
0.69
Interest Coverage 18.94
ABBV's Interest Coverage is ranked higher than
57% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.63 vs. ABBV: 18.94 )
ABBV' s 10-Year Interest Coverage Range
Min: 18.94   Max: 9999.99
Current: 18.94

18.94
9999.99
F-Score: 6
Z-Score: 4.25
M-Score: -2.75
WACC vs ROIC
14.17%
31.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.09
ABBV's Operating margin (%) is ranked higher than
87% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.10 vs. ABBV: 17.09 )
ABBV' s 10-Year Operating margin (%) Range
Min: 20.75   Max: 34.7
Current: 17.09

20.75
34.7
Net-margin (%) 8.89
ABBV's Net-margin (%) is ranked higher than
79% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. ABBV: 8.89 )
ABBV' s 10-Year Net-margin (%) Range
Min: 19.68   Max: 32.62
Current: 8.89

19.68
32.62
ROE (%) 47.04
ABBV's ROE (%) is ranked higher than
99% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. ABBV: 47.04 )
ABBV' s 10-Year ROE (%) Range
Min: 57.54   Max: 199.32
Current: 47.04

57.54
199.32
ROA (%) 7.41
ABBV's ROA (%) is ranked higher than
82% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. ABBV: 7.41 )
ABBV' s 10-Year ROA (%) Range
Min: 14.69   Max: 35.17
Current: 7.41

14.69
35.17
ROC (Joel Greenblatt) (%) 98.61
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. ABBV: 98.61 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 147.23   Max: 244.26
Current: 98.61

147.23
244.26
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABBV Guru Trades in Q1 2014

Joel Greenblatt 229,149 sh (+120.38%)
Jim Simons 2,796,900 sh (+54.56%)
PRIMECAP Management 6,335,722 sh (+8.29%)
Mario Gabelli 10,462 sh (+3.79%)
Murray Stahl 35,882 sh (+1.69%)
Pioneer Investments 2,045,676 sh (+0.42%)
Dodge & Cox 36,701 sh (+0.14%)
Jeff Auxier 78,440 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Tom Russo 86,777 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
John Hussman 303,250 sh (unchged)
Paul Tudor Jones Sold Out
David Dreman Sold Out
Vanguard Health Care Fund Sold Out
Manning & Napier Advisors, Inc 146,077 sh (-2%)
Bill Frels 269,936 sh (-3.49%)
Ken Fisher 627,139 sh (-45.03%)
Steven Cohen 519,107 sh (-52.3%)
George Soros 350,000 sh (-69.5%)
Jeremy Grantham 66,200 sh (-76.7%)
» More
Q2 2014

ABBV Guru Trades in Q2 2014

Louis Moore Bacon 185,000 sh (New)
Lee Ainslie 3,235,133 sh (New)
Jana Partners 75,000 sh (New)
NWQ Managers 83,878 sh (New)
Paul Tudor Jones 257,344 sh (New)
Ken Fisher 1,104,609 sh (+76.13%)
Manning & Napier Advisors, Inc 192,029 sh (+31.46%)
Tom Russo 86,777 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 36,649 sh (-0.14%)
PRIMECAP Management 6,304,122 sh (-0.5%)
Mario Gabelli 10,382 sh (-0.76%)
John Hussman 300,000 sh (-1.07%)
Pioneer Investments 2,014,581 sh (-1.52%)
Murray Stahl 35,273 sh (-1.7%)
Bill Frels 264,316 sh (-2.08%)
Jeff Auxier 73,421 sh (-6.4%)
Jim Simons 2,233,600 sh (-20.14%)
George Soros 150,000 sh (-57.14%)
Joel Greenblatt 88,923 sh (-61.19%)
» More
Q3 2014

ABBV Guru Trades in Q3 2014

Steve Mandel 5,247,201 sh (New)
Andreas Halvorsen 10,769,105 sh (New)
Steven Cohen 184,300 sh (New)
John Paulson 13,000,000 sh (New)
George Soros 1,537,146 sh (+924.76%)
Lee Ainslie 4,723,578 sh (+46.01%)
Jana Partners 100,000 sh (+33.33%)
Dodge & Cox 38,849 sh (+6%)
NWQ Managers 85,948 sh (+2.47%)
PRIMECAP Management 6,454,836 sh (+2.39%)
Paul Tudor Jones 261,700 sh (+1.69%)
Westport Asset Management 180,000 sh (unchged)
Tom Russo 86,777 sh (unchged)
Pioneer Investments 2,601,836 sh (unchged)
Mario Gabelli 10,382 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Murray Stahl 35,265 sh (-0.02%)
Bill Frels 263,837 sh (-0.18%)
Manning & Napier Advisors, Inc 186,088 sh (-3.09%)
Ken Fisher 999,768 sh (-9.49%)
Louis Moore Bacon 80,000 sh (-56.76%)
Jeff Auxier 27,371 sh (-62.72%)
John Hussman 100,000 sh (-66.67%)
Jim Simons 722,355 sh (-67.66%)
Joel Greenblatt 9,460 sh (-89.36%)
» More
Q4 2014

ABBV Guru Trades in Q4 2014

Jean-Marie Eveillard 1,016,097 sh (New)
Mario Gabelli 34,557 sh (+232.85%)
Pioneer Investments 3,102,193 sh (+19.23%)
NWQ Managers 96,015 sh (+11.71%)
PRIMECAP Management 6,578,886 sh (+1.92%)
Bill Frels 267,837 sh (+1.52%)
Manning & Napier Advisors, Inc 187,451 sh (+0.73%)
Robert Bruce 232,915 sh (+0.7%)
Ken Fisher 1,001,105 sh (+0.13%)
John Hussman 100,000 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Steve Mandel Sold Out
John Paulson Sold Out
Lee Ainslie Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Tom Russo 86,718 sh (-0.07%)
Murray Stahl 35,158 sh (-0.3%)
Jeff Auxier 27,071 sh (-1.1%)
Dodge & Cox 38,055 sh (-2.04%)
Joel Greenblatt 8,759 sh (-7.41%)
Louis Moore Bacon 30,044 sh (-62.45%)
Jim Simons 217,900 sh (-69.83%)
Paul Tudor Jones 12,914 sh (-95.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-12-31 Sold Out 4%$52.9 - $69.71 $ 60.27-5%0
John Paulson 2014-12-31 Sold Out 3.1%$52.9 - $69.71 $ 60.27-5%0
Andreas Halvorsen 2014-12-31 Sold Out 2.5%$52.9 - $69.71 $ 60.27-5%0
Steve Mandel 2014-12-31 Sold Out 1.2%$52.9 - $69.71 $ 60.27-5%0
George Soros 2014-12-31 Sold Out 0.66%$52.9 - $69.71 $ 60.27-5%0
Jean-Marie Eveillard 2014-12-31 New Buy0.16%$52.9 - $69.71 $ 60.27-4%1016097
Mario Gabelli 2014-12-31 Add 232.85%0.01%$52.9 - $69.71 $ 60.27-4%34557
John Paulson 2014-09-30 New Buy3.1%$52.05 - $59.62 $ 60.279%13000000
Andreas Halvorsen 2014-09-30 New Buy2.5%$52.05 - $59.62 $ 60.279%10769105
Lee Ainslie 2014-09-30 Add 46.01%1.26%$52.05 - $59.62 $ 60.279%4723578
Steve Mandel 2014-09-30 New Buy1.2%$52.05 - $59.62 $ 60.279%5247201
John Hussman 2014-09-30 Reduce -66.67%0.87%$52.05 - $59.62 $ 60.279%100000
George Soros 2014-09-30 Add 924.76%0.6%$52.05 - $59.62 $ 60.279%1537146
Joel Greenblatt 2014-09-30 Reduce -89.36%0.06%$52.05 - $59.62 $ 60.279%9460
Lee Ainslie 2014-06-30 New Buy2.6%$46.46 - $56.79 $ 60.2715%3235133
Joel Greenblatt 2014-06-30 Reduce -61.19%0.11%$46.46 - $56.79 $ 60.2715%88923
George Soros 2014-06-30 Reduce -57.14%0.1%$46.46 - $56.79 $ 60.2715%150000
Ken Fisher 2014-06-30 Add 76.13%0.06%$46.46 - $56.79 $ 60.2715%1104609
NWQ Managers 2014-06-30 New Buy0.05%$46.46 - $56.79 $ 60.2715%83878
George Soros 2014-03-31 Reduce -69.5%0.35%$46.83 - $53.68 $ 60.2719%350000
Vanguard Health Care Fund 2014-03-31 Sold Out 0.28%$46.83 - $53.68 $ 60.2719%0
Joel Greenblatt 2014-03-31 Add 120.38%0.1%$46.83 - $53.68 $ 60.2719%229149
Ken Fisher 2014-03-31 Reduce -45.03%0.06%$46.83 - $53.68 $ 60.2719%627139
David Dreman 2014-03-31 Sold Out 0.02%$46.83 - $53.68 $ 60.2719%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

John Paulson's Top 5 New Holdings For Q3
John Paulson (Trades, Portfolio)’s hedge fund Paulson & Co. was founded in 1994 and has $22.8 billion in assets under management as of Jul 2014. The fund focuses primarily on event-driven arbitrage situations. Paulson’s top strategies, the Advantage and Advantage Plus funds, lost 4.8 percent and 3.9 percent this year through August, the New York Times reported. Read more...
The 5 Most-Owned Spin-Offs of Investment Gurus
Numerous financiers, including Joel Greenblatt (Trades, Portfolio), have posited that investors can beat the market by investing in spin-offs – small portions of larger companies separated to stand as their own, independent company. But is this true? This is a question that GuruFocus writer Vera Yuan pondered in her article, “Can Spin-Offs Beat the Market?” Her research concluded that 52 weeks after being spun off, all spun-off companies since 2009 collectively outperformed the market by 84.28%. For this reason, GuruFocus introduced the “Spin-Off List” screener, which tracks all companies spun off since 2013. Read more...
Lountzis Asset Management Comments on Abbvie
ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.00
ABBV's P/E(ttm) is ranked higher than
74% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.60 vs. ABBV: 25.00 )
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 30.3
Current: 25

9.86
30.3
Forward P/E 11.89
ABBV's Forward P/E is ranked higher than
95% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.14 vs. ABBV: 11.89 )
N/A
PE(NRI) 25.90
ABBV's PE(NRI) is ranked higher than
74% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.50 vs. ABBV: 25.90 )
ABBV' s 10-Year PE(NRI) Range
Min: 9.85   Max: 30.31
Current: 25.9

9.85
30.31
P/B 19.70
ABBV's P/B is ranked lower than
51% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. ABBV: 19.70 )
ABBV' s 10-Year P/B Range
Min: 15.75   Max: 25.22
Current: 19.7

15.75
25.22
P/S 4.60
ABBV's P/S is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.01 vs. ABBV: 4.60 )
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 5.72
Current: 4.6

2.83
5.72
PFCF 19.50
ABBV's PFCF is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 19.50 )
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 23.55
Current: 19.5

8.64
23.55
POCF 17.85
ABBV's POCF is ranked higher than
80% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.53 vs. ABBV: 17.85 )
ABBV' s 10-Year POCF Range
Min: 8.19   Max: 20.87
Current: 17.85

8.19
20.87
EV-to-EBIT 19.24
ABBV's EV-to-EBIT is ranked higher than
80% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. ABBV: 19.24 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 22.2
Current: 19.24

10.3
22.2
Current Ratio 2.65
ABBV's Current Ratio is ranked higher than
58% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.36 vs. ABBV: 2.65 )
ABBV' s 10-Year Current Ratio Range
Min: 1.22   Max: 2.82
Current: 2.65

1.22
2.82
Quick Ratio 2.49
ABBV's Quick Ratio is ranked higher than
63% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ABBV: 2.49 )
ABBV' s 10-Year Quick Ratio Range
Min: 1.06   Max: 2.65
Current: 2.49

1.06
2.65
Days Inventory 75.35
ABBV's Days Inventory is ranked higher than
86% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.90 vs. ABBV: 75.35 )
ABBV' s 10-Year Days Inventory Range
Min: 34.3   Max: 89.28
Current: 75.35

34.3
89.28
Days Sales Outstanding 73.05
ABBV's Days Sales Outstanding is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.97 vs. ABBV: 73.05 )
ABBV' s 10-Year Days Sales Outstanding Range
Min: 79.87   Max: 93.3
Current: 73.05

79.87
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.90
ABBV's Dividend Yield is ranked higher than
85% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. ABBV: 2.90 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 2.9

0.85
3.44
Dividend Payout 1.51
ABBV's Dividend Payout is ranked higher than
66% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. ABBV: 1.51 )
ABBV' s 10-Year Dividend Payout Range
Min: 0.57   Max: 1.36
Current: 1.51

0.57
1.36
Yield on cost (5-Year) 2.90
ABBV's Yield on cost (5-Year) is ranked higher than
77% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. ABBV: 2.90 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 2.9

0.85
3.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.14
ABBV's Price/Median PS Value is ranked higher than
81% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. ABBV: 1.14 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 1.1
Current: 1.14

0.68
1.1
Earnings Yield (Greenblatt) 5.40
ABBV's Earnings Yield (Greenblatt) is ranked higher than
80% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ABBV: 5.40 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 9.7
Current: 5.4

4.5
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany, 0QCV.UK, ABBV.Mexico,
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper! Feb 21 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
The Gabelli ABC Fund Merger and Arbitrage – “The Deal Fund” Q4 Commentary Feb 04 2015 
AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
Looking Ahead of Wall Street: Gilead Sciences, Chipotle, Twitter Feb 03 2015 
Google Joins Biogen In The Fight Against Multiple Sclerosis Jan 29 2015 
What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 


More From Other Websites
Wall St. little changed after two-day drop, data Mar 05 2015
AbbVie to buy leukemia drugmaker Pharmacyclics for $21B Mar 05 2015
Why AbbVie's Stock Is Selling Off After Its $21 Billion Deal Mar 05 2015
AbbVie in $21 Billion Biotech Deal Mar 05 2015
U.S. stocks flirt with records ahead of key jobs report Mar 05 2015
AbbVie snags Pharmacyclics -- and its star drug Imbruvica -- for $21B (Video) Mar 05 2015
US stocks edge higher; Pharmacyclics jumps on AbbVie bid Mar 05 2015
After Pharmacyclics, Who's Next in Biotech M&A? Mar 05 2015
AbbVie buying Pharmacyclics for $21B Mar 05 2015
AbbVie's $21B Pharmacyclics Buy A Red Flag For Deal-Crazy Sector Mar 05 2015
US STOCKS-Wall St little changed after 2-day drop, data Mar 05 2015
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
Sunnyvale's Pharmacyclics sells for $21 billion to AbbVie Mar 05 2015
Three reasons why AbbVie bought Sunnyvale's Pharmacyclics for $21B Mar 05 2015
AbbVie Emerges With $21 Billion Deal in Fight to ‘the Very End’ Mar 05 2015
Pharmacyclics: Johnson & Johnson Would Have Made Way More Sense Mar 05 2015
Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal Mar 05 2015
Ringling Bros. Circus to Remove Elephant Act in Conservation Bid Mar 05 2015
Thu., March 5: Watch Costco on Strong Earnings Mar 05 2015
AbbVie to Acquire Pharmacyclics: What Wall Street's Saying Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK